The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Introduction
============

Financial transactions between the industry and physicians introduce potential conflicts of interest \[[@REF1]-[@REF2]\], which may translate to patient care \[[@REF3]\]. To improve transparency, the Sunshine Act, implemented in 2010, mandated the disclosure of industry payments to physicians \[[@REF4]\]. Industry payment trends have since been studied for several specialties \[[@REF5]-[@REF10]\]; however, the literature on trends of payments for neurological subspecialties is lacking \[[@REF11]\]. We aimed to explore payments from pharmaceutical and device manufacturing companies to various subspecialties of neurology.

Materials and methods
=====================

The Open Payments Program (OPP) data (<https://openpaymentsdata.cms.gov>) on industry-to-physician payments for the years 2014-2018 were extracted for general neurology, neuromuscular, neurophysiology, and vascular neurology. Subspecialty payments data for 2014-2018 were combined into a single dataset and the variable 'name of associated covered drug or biological' was used to sort the combined dataset. Type of 'drug or biological' for each data point was then studied to ascertain the subspecialty; for example, Tysabri or Tecfidera would suggest the 'multiple sclerosis/neuroimmunology' subspecialty while Vimpat or Aptiom would belong to the 'epilepsy' subspecialty. In the 'associated covered drug or biological' field, we excluded missing data (comprising approximately 3%) and drugs or biologicals with a frequency of fewer than 50 times (around 1%). All payment categories were analyzed, including food, travel, research, education, and consulting fees. All data analysis was conducted in SAS version 9.4 (SAS Institute, Cary, NC).

Results
=======

In 2014, industry-to-physician payments for all neurology subspecialties in the category of drugs and devices were 64 million USD. The three neurology subspecialties receiving the most industry payments were: multiple sclerosis/neuroimmunology (57.1% of total payments), movement disorders (14.7%), and epilepsy (14.3%) (Table [1](#TAB1){ref-type="table"}).

###### Industry payments by specialty in 2014 and 2018

MS - Multiple sclerosis; USD - United States dollars

  -------------------- ------------------------ ------------------------
  Specialty            2014 (million USD (%))   2018 (million USD (%))
  MS/Neuroimmunology   36.5 (57.1%)             35.1 (46.8%)
  Movement             9.6 (14.7%)              13.6 (18.1%)
  Epilepsy             9.0 (14.3%)              6.8 (9.0%)
  Headache             6.6 (10.2%)              14.7 (19.6%)
  Stroke               2.1 (3.4%)               2.3 (3.1%)
  Neuromuscular        1.3 (0.2%)               2.5 (3.4%)
  Total                64                       75 
  -------------------- ------------------------ ------------------------

Of the top 10 medications, seven drugs were for multiple sclerosis, and one each was for movement disorders, headache, and epilepsy (Table [2](#TAB2){ref-type="table"}).

###### Top 10 drugs: 2014 and 2018

MS - Multiple sclerosis

  ------ -------------------- ----------- ------ -------------------- -----------
  2014   Specialty            Drug        2018   Specialty            Drug
  1      MS/Neuroimmunology   Aubagio     1      MS/Neuroimmunology   Aubagio
  2      MS/Neuroimmunology   Copaxone    2      MS/Neuroimmunology   Lemtrada
  3      Movement Disorders   Azilect     3      Headache and Pain    Aimovig
  4      MS/Neuroimmunology   Tecfidera   4      MS/Neuroimmunology   Tysabri
  5      Headache and Pain    Botox       5      MS/Neuroimmunology   Ocrevus
  6      MS/Neuroimmunology   Tysabri     6      MS/Neuroimmunology   Tecfidera
  7      MS/Neuroimmunology   Plegridy    7      Movement Disorders   Nuplazid
  8      MS/Neuroimmunology   Gilenya     8      Movement Disorders   Austedo
  9      MS/Neuroimmunology   Ampyra      9      Headache and Pain    Ajovy
  10     Epilepsy             Aptiom      10     Epilepsy             Aptiom
  ------ -------------------- ----------- ------ -------------------- -----------

By 2018, the industry-to-physician payments increased by 16% to a total of 75 million USD. The three subspecialties receiving the most industry payments in 2018 were: multiple sclerosis/neuroimmunology (46.8% of total payments), headache (19.6%), and movement disorders (18.1%). Of the top 10 medications, five drugs were for multiple sclerosis, two each for headache and movement disorders, and one was for epilepsy (Table [2](#TAB2){ref-type="table"}). From 2014 to 2018, there were notable changes in the subspecialty distribution of these industry-to-physician payments (Table [1](#TAB1){ref-type="table"}). For example, payments increased for medications related to headache (from 10.2% in 2014 to 19.6% in 2018), neuromuscular disorders (from 0.2 to 3.4%), and movement disorders (14.7% to 18.1%), while the payments decreased for medications related to multiple sclerosis/neuroimmunology (from 57.1% to 46.8%) and epilepsy (from 14.3% to 9%) and remained stable for stroke-related medications (3.4% to 3.1%).

Discussion
==========

In this study, we used publicly available databases to explore and report payments from industry to various neurology subspecialties between 2014 and 2018.

There was a significant increase in the total payment to neurology from 2014 to 2018 by 16%. Among them, industry payments for movement disorders, headache, and neuromuscular were increased. Especially, headache and neuromuscular had a substantial increase in these four years. It is consistent with the fact that headache drugs took the third and ninth place of the highest-paid drugs in 2018. There had been no headache medications approved by the Food and Drug Administration (FDA) from 2014 until 2018 when two new drugs (Fremanezumab and Erenumab) came to market (<https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018>) (Table [3](#TAB3){ref-type="table"}).

###### FDA approved drugs 2014-2018

MS - Multiple sclerosis; FDA - Food and Drug Administration

  ------ ----------------------- ------------ --------------------
  Year   Drug Name               Brand name   Indication
  2014   Droxidopa               Northera     Neuromuscular
         Florbetaben             Neuraceq     Dementia
         Peginterferon beta 1a   Plegridy     MS/Neuroimmunology
  2015   Idarucizumab            Praxbind     Stroke
  2016   Brivaracetam            Briviact     Epilepsy
         Pimavanserin            Nuplazid     Movement
         Daclizumab              Zinbryta     MS/Neuroimmunology
         Eteplirsen              Exondys 51   Neuromuscular
         Nusinersen              Spinraza     Neuromuscular
  2017   Edaravone               Radicava     Neuromuscular
         Valbenazine             Ingrezza     Movement
         Deutetrabenazine        Austedo      Movement
         Ocrelizumab             Ocrevus      MS
         Safinamide              Xadago       Movement
         Deflazacort             Emflaza      Neuromuscular
  2018   Amifampridine           Firdapse     Neuromuscular
         Inotersen               Tegsedi      Neuromuscular
         Fremanezumab            Ajovy        Headache
         Stiripentol             Diacomit     Epilepsy
         Migalastat              Galafold     Neuromuscular
         Patisiran               Onpattro     Neuromuscular
         Cannabidiol             Epidioloex   Epilepsy
         Erenumab                Aimovig      Headache
  ------ ----------------------- ------------ --------------------

Similarly, there have been many breakthrough advances in the neuromuscular disease field such as Nusinersen for spinal muscular atrophy. According to the FDA data, among 23 newly approved drugs with a neurological indication between 2014 and 2018, nine of them were indicated for neuromuscular disorders. It is also reported that there are currently nearly 200 products in the therapeutic pipeline for neuromuscular disorders and we presume the growth of this field will continue. On the other hand, there is a slight reduction in MS/neuroimmunology, and epilepsy in four years, although six out of the 10 highest paid drug in 2018 were therapies for MS/neuroimmunology. This could be related to the fact that there were no newly FDA-approved MS/neuroimmunology drugs and only one epilepsy drug (Cannabidiol) in 2018. Given that the industry payment for each drug includes the fee for food, travel, research, education, and consulting, the newly approved drug would likely to be received more investment to increase awareness among neurologists. Further studies are needed to evaluate if there is any potential for influence on thought leaders in the field, as has been published before, along with the focus on educational components for newly approved medications \[[@REF12]-[@REF14]\].

Conclusions
===========

From 2014 through 2018, the distribution of industry-to-physician payments for various neurology subspecialties showed notable changes. Payments to the subspecialties of headache, neuromuscular disorders, and movement disorders increased, likely related to the introduction of newer medications in these fields. Physician education and knowledge of the trends and potential motives of industry spending is critical to address any potential bias in prescribing medications when alternatives may be available.
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